Company
AstraZeneca
Official Name: AstraZeneca plc
Headquarters: Cambridge, United Kingdom
Founded: 6 April 1999
Employees: 83,100
CEO: Mr. Pascal Soriot D.V.M., M.B.A.
Market Cap
£186.90 Billion
GBP as of July 1, 2024
US$236.45 Billion
Company Description
AstraZeneca PLC is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company. AstraZeneca develops, manufactures, and sells pharmaceuticals and biotechnology products to treat major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
| AbbVie | $295.34 B |
| Novartis | $219.78 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
AstraZeneca plc has the following listings and related stock indices.
Stock: LSE: AZN wb_incandescent
Stock: BCBA: AZN wb_incandescent
Stock: BMV: AZNN wb_incandescent
Stock: FSX: ZEG wb_incandescent
Stock: FSX: ZEGA wb_incandescent
Stock: OMX: AZN wb_incandescent
Stock: OTC: AZNCF wb_incandescent
Stock: NASDAQ: AZN wb_incandescent
Stock: XETR: ZEG wb_incandescent
Product & Services
Pharmaceutical products
Key People
Leif Johansson (Chairman) Pascal Soriot (CEO)
Financials
Revenue: US$37.417 billion (2021)
Operating income: US$1.056 billion (2021)
Net income: US$0.115 billion (2021)
Total assets: US$105.363 billion (2021)
Total equity: US$39.287 billion (2021)